Deutsche Bank AG Purchases 75,994 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Deutsche Bank AG boosted its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 53.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 217,723 shares of the company's stock after buying an additional 75,994 shares during the period. Deutsche Bank AG owned approximately 0.06% of Recursion Pharmaceuticals worth $1,472,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Barclays PLC boosted its stake in shares of Recursion Pharmaceuticals by 53.9% in the 3rd quarter. Barclays PLC now owns 697,432 shares of the company's stock valued at $4,596,000 after purchasing an additional 244,278 shares in the last quarter. Arkadios Wealth Advisors acquired a new stake in shares of Recursion Pharmaceuticals in the 4th quarter valued at approximately $84,000. Brighton Jones LLC boosted its stake in shares of Recursion Pharmaceuticals by 49.4% in the 4th quarter. Brighton Jones LLC now owns 20,261 shares of the company's stock valued at $137,000 after purchasing an additional 6,699 shares in the last quarter. Impact Partnership Wealth LLC acquired a new stake in shares of Recursion Pharmaceuticals in the 4th quarter valued at approximately $90,000. Finally, Exchange Traded Concepts LLC boosted its stake in shares of Recursion Pharmaceuticals by 101.6% in the 4th quarter. Exchange Traded Concepts LLC now owns 50,761 shares of the company's stock valued at $343,000 after purchasing an additional 25,579 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Trading Up 7.6%

NASDAQ RXRX traded up $0.31 during trading hours on Tuesday, reaching $4.39. The company's stock had a trading volume of 22,681,924 shares, compared to its average volume of 13,471,796. The firm has a fifty day simple moving average of $5.09 and a 200-day simple moving average of $6.48. The stock has a market cap of $1.78 billion, a P/E ratio of -2.87 and a beta of 0.99. Recursion Pharmaceuticals, Inc. has a 52 week low of $3.79 and a 52 week high of $12.36. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm had revenue of $14.75 million for the quarter, compared to the consensus estimate of $18.12 million. During the same quarter in the previous year, the business posted ($0.39) EPS. The firm's revenue for the quarter was up 7.2% compared to the same quarter last year. Equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Cowen restated a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Needham & Company LLC reduced their price target on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Morgan Stanley reduced their price target on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 10th. Finally, Leerink Partners dropped their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a report on Friday, February 28th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $7.60.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.